SCHEMBL5540744

SCHEMBL5540744

COc1ccc(-c2ccc3n[c]sc3c2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 2/20 0.44
MAP4K4 O95819 1/20 0.43
NT5E P21589 1/20 0.43
DYRK1A Q13627 2/20 0.42
SULT1A1 P50225 1/20 0.41
ABCB1 P08183 1/20 0.41
BCR P11274 1/20 0.41
LIMK1 P53667 1/20 0.40
KDR P35968 1/20 0.40
APP P05067 1/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
TP53 P04637 1/20 0.40
MAPK1 P28482 1/20 0.40
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
KDM4E B2RXH2 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5535853 0.87 KDR (0.43) ABL1MAP4K4NT5EDYRK1AABCB1
SCHEMBL533470 0.86 CYP1A2 (0.49) DYRK1AAPPNPC1RAB9ASMN1; SMN2
SCHEMBL5535847 0.81 PIK3CA (0.50) ABL1MAP4K4DYRK1ALIMK1ALDH1A1
SCHEMBL2160767 0.76 RAB9A (0.43) DYRK1ANPC1RAB9ASMN1; SMN2TP53
SCHEMBL227271 0.72 KMT2A (0.53) NPC1RAB9ASMN1; SMN2TP53MAPK1
SCHEMBL29992983 0.72 NPC1 (0.56) ABL1MAP4K4DYRK1ALIMK1APP
SCHEMBL13862753 0.71 NPC1 (0.56) ABL1SULT1A1APPNPC1RAB9A
SCHEMBL13862776 0.70 CYP3A4 (0.77) APPTP53ALDH1A1
SCHEMBL31114769 0.70 CYP3A4 (0.77) APPTP53ALDH1A1
SCHEMBL212513 0.70 MAPT (0.44) DYRK1AAPPNPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ABL1 2364/4885MAP4K4 2973/4885NT5E 3182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.